|
1
|
Nemeth K, Bayraktar R, Ferracin M and
Calin GA: Non-coding RNAs in disease: From mechanisms to
therapeutics. Nat Rev Genet. Nov 15–2023.doi:
10.1038/s41576-023-00662-1 (Epub ahead of print). PubMed/NCBI
|
|
2
|
Jin Y and Fan Z: New insights into the
interaction between m6A modification and lncRNA in cancer drug
resistance. Cell Prolif. e135782023.doi: 10.1111/cpr.13578 (Epub
ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Qi HL, Li CS, Qian CW, Xiao YS, Yuan YF,
Liu QY and Liu ZS: The long noncoding RNA, EGFR-AS1, a target of
GHR, increases the expression of EGFR in hepatocellular carcinoma.
Tumour Biol. 37:1079–1089. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Atef MM, Amer AI, Hafez YM, Elsebaey MA,
Saber SA and Abd ES: Long non-coding RNA EGFR-AS1 in colorectal
cancer: Potential role in tumorigenesis and survival via miRNA-133b
sponge and EGFR/STAT3 axis regulation. Br J Biomed Sci. 78:122–129.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dhamodharan S, Rose MM, Chakkarappan SR,
Umadharshini KV, Arulmurugan R, Subbiah S, Inoue I and Munirajan
AK: Genetic variant rs10251977 (G>A) in EGFR-AS1 modulates the
expression of EGFR isoforms A and D. Sci Rep. 11:88082021.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang A, Jiang A, Gan X, Wang Z, Huang J,
Dong K, Liu B, Wang L and Chen M: EGFR-AS1 promotes bladder cancer
progression by upregulating EGFR. Biomed Res Int. 2020:66659742020.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yuan S, Luan X, Chen H, Shi X and Zhang X:
Long non-coding RNA EGFR-AS1 sponges micorRNA-381 to upregulate
ROCK2 in bladder cancer. Oncol Lett. 19:1899–1905. 2020.PubMed/NCBI
|
|
8
|
Feng Z, Li X, Qiu M, Luo R, Lin J and Liu
B: LncRNA EGFR-AS1 upregulates ROCK1 by sponging miR-145 to promote
esophageal squamous cell carcinoma cell invasion and migration.
Cancer Biother Radiopharm. 35:66–71. 2020.PubMed/NCBI
|
|
9
|
Qi H, Wang S, Wu J, Yang S, Gray S, Ng C,
Du J, Underwood MJ, Li MY and Chen GG: EGFR-AS1/HIF2A regulates the
expression of FOXP3 to impact the cancer stemness of
smoking-related non-small cell lung cancer. Ther Adv Med Oncol.
11:4324970282019. View Article : Google Scholar
|
|
10
|
Wang A, Bao Y, Wu Z, Zhao T, Wang D, Shi
J, Liu B, Sun S, Yang F, Wang L and Qu L: Long noncoding RNA
EGFR-AS1 promotes cell growth and metastasis via affecting HuR
mediated mRNA stability of EGFR in renal cancer. Cell Death Dis.
10:1542019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xu YH, Tu JR, Zhao TT, Xie SG and Tang SB:
Overexpression of lncRNA EGFR-AS1 is associated with a poor
prognosis and promotes chemotherapy resistance in non-small cell
lung cancer. Int J Oncol. 54:295–305. 2019.PubMed/NCBI
|
|
12
|
Dong ZQ, Guo ZY and Xie J: The lncRNA
EGFR-AS1 is linked to migration, invasion and apoptosis in glioma
cells by targeting miR-133b/RACK1. Biomed Pharmacother.
118:1092922019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hu J, Qian Y, Peng L, Ma L, Qiu T, Liu Y,
Li X and Chen X: Long Noncoding RNA EGFR-AS1 Promotes Cell
Proliferation by Increasing EGFR mRNA stability in gastric cancer.
Cell Physiol Biochem. 49:322–334. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tan D, Chong FT, Leong HS, Toh SY, Lau DP,
Kwang XL, Zhang X, Sundaram GM, Tan GS, Chang MM, et al: Long
noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor
addiction and modulates treatment response in squamous cell
carcinoma. Nat Med. 23:1167–1175. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhu D, Ouyang X, Zhang Y, Yu X, Su K and
Li L: A promising new cancer marker: Long noncoding RNA EGFR-AS1.
Front Oncol. 13:11304722023. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li J and Wang H: H3K27ac-activated
EGFR-AS1 promotes cell growth in cervical cancer through
ACTN4-mediated WNT pathway. Biol Direct. 17:32022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ahn S, Pinheiro PS, Mcclure LA, Hernandez
DR, Caban-Martinez AJ and Lee DJ: An examination of psychometric
properties of study quality assessment scales in meta-analysis:
Rasch measurement model applied to the firefighter cancer
literature. PLoS One. 18:e2844692023. View Article : Google Scholar
|
|
18
|
Wang W, Yuan F and Xu J: The prognostic
role of long noncoding RNA CRNDE in cancer patients: A systematic
review and meta-analysis. Neoplasma. 66:73–82. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
de Oliveira IR, Santos-Jesus R, Po AL and
Poolsup N: Extracting numerical data from published reports of
pharmacokinetics investigations: Method description and validation.
Fundam Clin Pharmacol. 17:471–472. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Qi HL, Zhuang BJ, Li CS and Liu QY:
Peri-operative use of sorafenib in liver transplantation: A
time-to-event meta-analysis. World J Gastroenterol. 21:1636–1640.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tierney JF, Stewart LA, Ghersi D, Burdett
S and Sydes MR: Practical methods for incorporating summary
time-to-event data into meta-analysis. Trials. 8:162007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hou XR, Zhang ZD, Cao XL and Wang XP: Long
noncoding RNAs, glucose metabolism and cancer (Review). Oncol Lett.
26:3402023. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xue Y, Zhang J, Hou J and Wang X: EGFR-AS1
promotes nonsmall cell lung cancer (NSCLC) progression via
downregulating the miR-524-5p/DRAM1 axis and inhibiting autophagic
lysosomal degradation. J Oncol. 2022:44025362022. View Article : Google Scholar : PubMed/NCBI
|
